

ANDREA DE VITO

VIA Francesco Cetti, 07100 Sassari, ITALY

Email: andreadevitoaho@gmail.com;

Phone Number: +39 340 470 4834

Orcid: 0000-0002-8265-5400

Scopus: <https://www.scopus.com/authid/detail.uri?authorId=57210853735>

Researchgate: <https://www.researchgate.net/profile/Andrea-De-Vito>



WORK HISTORY

S.C. INFECTIOUS DISEASES – UNIVERSITY OF SASSARI

Research fellow in Infectious Diseases | Sassari, Italy | January 2025 - Current

S.S.D INFECTIOUS DISEASES

Term-contract worker in Infectious Diseases | Nuoro, Italy | December 2024 - Current

VOGUE Trial

Sub-Investigator | Sassari, Italy | September 2023 – Current

UNIVERSITY OF SASSARI

PhD student in Infectious Diseases | Sassari, Italy | November 2021 – October 2024

EDOLAS STUDY

Sub-Investigator | Sassari, Italy | April 2021 – Current

S.C. INFECTIOUS DISEASES – UNIVERSITY OF SASSARI

Term-contract worker in Infectious Diseases | Sassari, Italy | November 2020 – May 2022

TOCIVID-19

Sub-Investigator | Sassari, Italy | March 2020 – July 2020

ARCA GROUP

Co-Investigator | Sassari, Italy | September 2019 – Current

Scientific Committee | December 2023 – Current

GEPPO STUDY

Co-Investigator | Sassari, Italy | September 2019 – Current

S.C. INFECTIOUS DISEASES – UNIVERSITY OF SASSARI

Registrar in Infectious Diseases | Sassari, Italy | November 2018 – October 2022

CISAI GROUP

Co-Investigator | Sassari, Italy | October 2018 – Current
Scientific Committee | November 2023 - Current

DIAMANTE STUDY

Co-Investigator | Sassari, Italy | October 2018 – May 2021

ICONA FOUNDATION STUDY

Co-Investigator | Sassari, Italy | October 2017 – Current

UNIVERSITY HOSPITAL OF WALES, INFECTIOUS DISEASE

Clinical Internship | Cardiff, Wales | September 2016 - December 2016
Erasmus Traineeship

UNIVERSITY OF BORDEAUX SEGALENE

Clinical Stage | Bordeaux, Nouvelle-Aquitaine | March 2013 - March 2013
Anatomic dissection stage - Anatomic workshop

Academic Supervision and Teaching

Co-Supervised 10 final theses for Medical Degree students.

Co-Supervised 1 final thesis for Nursing Degree students.

Co-Supervised 1 final thesis for Laboratory Science Degree students.

Conducted a 12-hour Infectious Disease Course for fourth-year Medical Degree students, Academic Year 2022/2023 and 2023/2024.

EDUCATION

Second-Level Master's in Biostatistics and Epidemiological Methodology

Pavia, Italy | January 2025 – Current

PhD student in Infectious Diseases

Sassari, Italy | November 2021 – October 2024

DIPLOMA IN INTERNISTIC ULTRASOUND

SIUMB – University of Pavia

2023

SPECIALIZATION IN INFECTIOUS DISEASES AND TROPICAL MEDICINE

University of Sassari

Sassari, Sardegna | 2022

- **Thesis:** Early antiviral therapy anti-SARS-CoV-2 reduces the risk of disease progression: a real-life experience

Supervisor: Professor Giordano Madeddu

MEDICAL LICENSE NUMBER 5998

Order of Physicians And Surgeons

Sassari, Italy, 2018

DEGREE IN MEDICINE AND SURGERY

University of Sassari

Sassari, Sardegna | 2017

- **Thesis:** Use of Dolutegravir in the clinical practice: a multicenter study between Italy and Wales –

Supervisor: Professor Giordano Madeddu;

- **Graduated summa cum laude**

HIGH SCHOOL DIPLOMA

Liceo Scientifico Enrico Fermi

Alghero, Sardegna | 2010

- Graduated with 84/100

SKILLS

- Use computerized database software to record findings and prepare reports.
- Use of Office package
- Use of Stata 16.1 for statistical analysis
- Excellent communication skills with medical personnel and patients

CERTIFICATIONS

- Cambridge English Level 1, Certificate in ESOL International (FIRST) B2
 - Good Practices Training (2018)
 - ACLS certificate (15/02/2022)
 - Ultrasound Diploma SIUMB (2023)
-

Speaker at national and International Conferences

- **U=U: IL PARADIGMA DA HIV A HCV**
Oristano 20/November/2020 - Recenti modificazioni epidemiologiche dell'infezione da HIV: un update dai dati nazionali e internazionali
- **Vivere e invecchiare con l'AIDS: HIV e attualità in malattie infettive**
Cagliari 05/Dicember/2020 - Dati epidemiologici regionali e nazionali
- **European Meeting on HIV & Hepatitis 2020**
Online 28-30/October/2020: Oral presentation: Treatment outcome among people living with HIV starting first-line rapid or GRT guided ART from 2015 to 2018
- **ECCMID 2021**
Online 9-12/July/2021 – Oral presentation: Early treatment with low-molecular-weight heparin reduces mortality rate of SARS-CoV-2 patients.
- **III Congresso Regionale SIMIT Sardegna**
Alghero 15-16/October 2021 – Attività protrombotica di SARS-CoV2 e ruolo dell'Eparina nei tools terapeutici
- **ICAR 2021**
Riccione 21-23/October 2021 – Oral Poster: Who could be eligible for long-acting antiretroviral treatment? A snapchat from Antiviral Response Cohort Analysis (ARCA) Italian cohort
- **I° Workshop CISAI sugli antibiotici attivi verso microrganismi MDR**
Milano 19/November/2021 – Faculty - Nuovi farmaci attivi su Gram-negativi: Meropenem-vaborbactam
- **SIMIT 2021**
Milano 28-30/November-01/Dicember 2021 – Chair: Infezione Da Hiv E Altre Infezioni
- **Vivere e invecchiare con l'AIDS: HIV e attualità in malattie infettive**
Cagliari 04/Dicember/2021 - Emersione del sommerso
- **La gestione personalizzata del PLWH nel lungo temine: strategie innovative a confronto**
Palermo 03-04/March/2022
- **Drive the Change in HIV 2.0**
Oristano 08/June/2022 - Esperienza Real Life: ARV e sistema nervoso centrale
- **ICAR 2022: 14° congresso nazionale**
Bergamo 15/June/2022 - Safety and efficacy of antiviral agents in SARS-CoV-2 infected patients: a real-life experience
- **Focus on ABSSI: Ascessi cutanei, Celluliti, Erisipela Infezioni del sito chirurgico**
Oristano 08/July/2022: esperienze cliniche in Medicina d'urgenza
- **Excellence in HIV: a lab for new generation – Sicilia Sardegna**
Webinar LIVE 24/June/2022
- **SIMIT Sardegna 2022: La terapia antivirale precoce anti SARS-CoV-2: esperienze real life**
Webinar LIVE 21-22/October/2022
- **SARS-CoV-2 EARLY TREATMENT, MMG E SINERGIE TERRITORIO-OSPEDALE**
Sassari 25/March/2023: Focus sulle potenziali interazioni tra farmaci
- **Drive the Change in HIV 3.0**
Oristano 31/March/2023 - Accendiamo i riflettori sul paziente con disordini cardiometabolici: la risposta con la nuova generazione di NNRTI
- **LHIVE my best Life**
Bari 14/April/2023: Breaking data with BIC/FTC/TAF in treatment experienced patients: Aging
- **ECCMID 2023**
Copenhagen, 15-18/April/2023: A new score to predict disease progression in SARS-CoV-2 infected people in the vaccines and early treatment era,

- **INHIMEGE 4.0**
Cagliari 28-29/November/2023: La gestione dell'infezione da HIV nella popolazione transgender (HIV management in transgender individuals)
- **SIMIT Sardegna 2023: Nuove frontiere della terapia antiretrovirale: iniezioni di speranza?**
Sassari 10-11/November/2023: Nuove frontiere della terapia antiretrovirale: iniezioni di speranza?
- **NEXT GEN IN INFECTIOUS DISEASES**
Florence, 30-31/January/2024: L'ottimizzazione nel paziente virosoppresso
- **CONGRESSO HIV & COINFECTION 10° ICONA FOUNDATION MEETING**
Rome, 6-7/February/2024: Understanding the discontinuation from 3TC/DTG and RPV/DTG to Triple Drug and Dual PI-Based therapies
- **HIV in clinical practice: the ESSENTIALS**
Alghero, 13-14/March/2024: Le esperienze dai Centri con Dual Therapies; Aging, comorbidità non infettive (metaboliche, CV, psichiatriche).
- **IWHOD 2024**
Vilamoura, 21-23/March/2024: Adapting Hiv Management During COVID-19: Evidence On linkage to care and antiretroviral therapy Initiation From The Icona Cohort
- **Drive the Change in HIV 4.0**
Oristano, 27/March/2024: Riflettori accesi sulla salute cardiometabolica in HIV: dalla teoria alla pratica clinica
- **ECCMID 2024**
Barcelona, 27-30/April/2024 – Assessing ChatGPT's theoretical knowledge and prescriptive accuracy in bacterial infections: a comparative study with residents and specialists
- **Tollerabilità dei farmaci antinfettivi e co-morbilità associate all'infezione da HIV**
Milano, 10/May/2024: PROGETTO SUSANA: REAL WORLD DATA SU NUOVI ANTIBIOTICI-Meropenem/Vaborbactam
- **Peer-to-Peer: HIV Academy**
Palermo, 21-22/May/2024: Chair
- **Pillole di Infettivologia**
Web, 11/June/2024: Long Term Treatment Success
- **ICAR 2024**
Rome, 19-21/June/2024: Switching from 3TC/DTG and RPV/DTG to Triple Drug and Dual PI-Based therapies for toxicity/intolerance: data from the ICONA cohort
- **LET'S MOVE to HIV Disease Awareness 3.0**
Rome, 25/June/2024: Inflammation & Cardiometabolic issues in HIV – today and the future
- **Piano Nazionale Arbovirosi 2020-2025. Approccio One health alle malattie trasmesse da vettori e nuove emergenze: focus sulla Dengue**
Cagliari, 11/July/2024: Clinica, iter diagnostico, terapia nei casi di Dengue
- **HIVR4P 2024, the 5th HIV Research for Prevention Conference**
Lima, 06-10/October/2024: Is the U=U status maintained after switching to a dual regimen? The answer from the Icona cohort Study

SCIENTIFIC PUBLICATION (index Journal)

1. Rossetti B, Gianmaria Baldin, Sterrantino G, Rusconi S, **De Vito A**, Giacometti A, Gagliardini R, Colafigli M, Capetti A, d'Ettorre G, Celani L, Lagi F, Ciccullo A, De Luca A, Di Giambenedetto S, Madeddu G. (2019) Efficacy and safety of dolutegravir-based regimens in

advanced HIV-infected naïve patients: results from a multicenter cohort study. *Antiviral Research*, Volume 169; <https://doi.org/10.1016/j.antiviral.2019.104552>.

2. Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, **De Vito A**, Babudieri S, Petrocelli M, Serra A, Bussu F, Ligas E, Salzano G, De Riu G. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. *Head & Neck*. 2020; 42(6):1252-1258. <https://doi.org/10.1002/hed.26204>
3. Vaira LA., Hopkins C., Salzano G., Petrocelli M., Melis A., Cucurullo M., Ferrari M., Gagliardini L., Pipolo C., Deiana G., Fiore V., De Vito A., Turra N., Canu S., Maglio A., Serra A., Bussu F., Madeddu G., Babudieri S., Giuseppe Fois A., Pirina P., Salzano FA., De Riu P., Biglioli F., De Riu G. Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study. *Head Neck*. 2020 Jul;42(7):1560-1569. doi: 10.1002/hed.26269.
4. **De Vito, A**, Geremia, N, Mameli, M. S, Fiore, V, Serra, P. A, Rocchitta, G. G. M, Nuvoli, S. M. F, Spanu, A, Lobrano, R, Cossu, A, Babudieri, S, Madeddu, G. (2020). Epidemiology, clinical aspects, laboratory diagnosis and treatment of rickettsial diseases in the mediterranean area during covid-19 pandemic: a review of the literature. *Mediterranean Journal of Hematology and Infectious Diseases*, 12(1), e2020056. <https://doi.org/10.4084/mjh.2020.056>
5. Bonfanti P, **De Vito A**, Ricci E, Menzaghi B, Orofino G, Squillace N, Molteni C, De Socio GV, Salomoni E, Celesia BM, Dentone C, Colombo V, Madeddu G. Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort. *Infect Drug Resist*. 2020;13:2291-2300. <https://doi.org/10.2147/IDR.S260449>
6. Vergori A, Gagliardini R, Gianotti N, Gori A, Lichtner M, Saracino A, **De Vito A**, Cascio A, Di Biagio A, Monforte AD, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Network. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤ 50 copies/mL: does estimated glomerular filtration rate matter? *International Journal of Antimicrobial Agents*. 2020 Sep:106154. <https://doi.org/10.1016/j.ijantimicag.2020.106154>.
7. Baratella E, Crivelli P, Marrocchio C, Bozzato AM, **De Vito A**, Madeddu G, Sadari L, Confalonieri M, Tenaglia L, Cova MA. Severity of lung involvement on chest X-rays in SARS-coronavirus-2 infected patients as a possible tool to predict clinical progression: an observational retrospective analysis of the relationship between radiological, clinical, and laboratory data. *J. bras. pneumol*. 2020; 46(5): e20200226. <https://doi.org/10.36416/1806-3756/e20200226>.
8. **De Vito A**, Geremia N, Fiore V, Princic E, Babudieri S, Madeddu G. Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy. *Eur Rev Med Pharmacol Sci*. 2020; 24(14): 7861-7868. https://doi.org/10.26355/eurrev_202007_22291
9. Geremia N, **De Vito A**, Gunnella S, Fiore V. Princic E, Panu Napodano CMD, Madeddu G, Babudieri S. A Case of Vasculitis-Like Skin Eruption Associated With COVID-19, *Infectious Diseases in Clinical Practice*: 2020 - Volume Publish Ahead of Print. doi: 10.1097/IPC.0000000000000952
10. Zinellu A, Arru F, **De Vito A**, Sassu A, Valdes G, Scano V, Zinellu E, Perra R, Madeddu G, Carru C, Pirina P, Mangoni AA, Babudieri S, Fois AG. The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients. *Eur J Clin Invest*. 2021

Jan;51(1):e13427. doi: 10.1111/eci.13427. Epub 2020 Oct 25. PMID: 33043447; PMCID: PMC7646002.

11. **A. De Vito**, G. Madeddu. Editorial – HIV and cancer during COVID-19 pandemic: sailing through the perfect storm. *Eur Rev Med Pharmacol Sci.* 2020; 24(24): 13103-4. 10.26355/eurrev_202012_24219
12. **A. De Vito**, N. Geremia, E. Princic, C. Fanelli, C.M. Panu Napodano, A.A. Muredda, V. Fiore, I. Maida, A.G. Fois, S. Babudieri, G. Madeddu. Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience. *Eur Rev Med Pharmacol Sci.* 2021; 25(1): 523-526. 10.26355/eurrev_202101_24424
13. Madeddu G., **De Vito A.**, Cozzi-Lepri A: Cingolani A. Maggiolo F. Perno CF. Gagliardini, R., Marchetti G. Saracino A. d'Arminio Monforte A. Antinori A. Girardi E. Time spent with viral load ≤ 200 copies/mL in a cohort of people with HIV seen for care in Italy during the U=U prevention campaign era, *AIDS.* 10.1097/QAD.0000000000002825
14. **De Vito A.**, Fiore V., Princic E., Geremia N., Panu Napodano CM., Muredda AA., Maida I., Madeddu G., Babudieri S. Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. *PLoS One.* 2021 Mar 16;16(3):e0248009. doi: 10.1371/journal.pone.0248009.
15. Fiore V., **De Vito A.**, Geremia N., Martineková P., Princic E., Babudieri S., Madeddu G. High-risk sexual behavior and HIV/STDs cascade of care in migrants: results from an Italian dedicated outpatient clinic. *J Infect Dev Ctries.* 2021 Mar 7;15(2):297-300. doi: 10.3855/jidc.13346.
16. **De Vito A.**, Madeddu G. Reply Letter - "Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis". *Eur Rev Med Pharmacol Sci.* 2021 Mar;25(5):2161-2162. doi: 10.26355/eurrev_202103_25203.
17. Fiore V., **De Vito A.**, Aloisio A., Donadu MG., Usai D., Zanetti S., Maida I., Madeddu G., Babudieri S. Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases. *Infect Dis (Lond).* 2021 Jun;53(6):473-475. doi: 10.1080/23744235.2021.1893898.
18. Dallochio RN., Dessì A., **De Vito A.**, Delogu G., Serra PA., Madeddu G. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? *Eur Rev Med Pharmacol Sci.* 2021 Mar;25(5):2435-2448. doi: 10.26355/eurrev_202103_25285
19. Zinellu A., **De Vito A.**, Scano V., Paliogiannis P., Fiore V., Madeddu G., Maida I., Zinellu E., Mangoni AA., Arru LB., Carru C., Babudieri S., Pirina P., Fois AG. The PaO₂/FiO₂ ratio on admission is independently associated with prolonged hospitalization in COVID-19 patients. *J Infect Dev Ctries.* 2021 Mar 31;15(3):353-359. doi: 10.3855/jidc.13288.
20. Vaira LA, **De Vito A.**, Deiana G, Pes C, Giovanditto F, Fiore V, Lechien JR, Saussez S, Policicchio D, Boccaletti R, Madeddu G, Babudieri S, Pazzola A, Bandiera F, Fois AG, Piana AF, Hopkins C, De Riu G. Systemic inflammatory markers and psychophysical olfactory scores in coronavirus disease 2019 patients: is there any correlation? *J Laryngol Otol.* 2021 Jun 29:1-6. doi: 10.1017/S0022215121001651.
21. Vaira L.A., Deiana G., Lechien J.R., De Vito A., Cossu A., Dettori M., Del Rio A., Saussez S., Madeddu G., Babudieri S., Fois A.G., Cocuzza C., Hopkins C., De Riu G., Piana A.F. Correlations Between Olfactory Psychophysical Scores and SARS-CoV-2 Viral Load in COVID-19 Patients. *Laryngoscope.* 2021, 131(10), 2312–2318.
22. Fiore V., De Vito A., Madeddu G., Babudieri S., "SARS-CoV-2 Vaccination Among Incarcerated People: A Barrier to Overcome. *Frontiers in Public Health.* 2021, 9; 704520.
23. Spanu A., Nuvoli S., Marongiu A., Gelo I., Mele L., De Vito A., Rondini M., Madeddu G. The diagnostic usefulness of ¹³¹I-spect/ct at both radioiodine ablation and during long-term follow-up in patients thyroidectomized for differentiated thyroid carcinoma: Analysis of

tissue risk factors ascertained at surgery and correlated with metastasis appearance. *Diagnostics*. 2021, 11(8); 1504.

24. Fiore V., De Vito A., Martineková P., Princic E., Geremia N., Madeddu G., Babudieri S. Infectious diseases screening approach among refugees: Results from a single-center study. *Journal of Infection in Developing Countries*, 2021, 15(6); 847–852.
25. Taramasso, L., **De Vito, A.**, Ricci, E. D., Orofino, G., Squillace, N., Menzaghi, B., Molteni, C., Gulminetti, R., De Socio, G. V., Pellicanò, G. F., Sarchi, E., Celesia, B. M., Calza, L., Rusconi, S., Valsecchi, L., Martinelli, C. V., Cascio, A., Maggi, P., Vichi, F., Angioni, G., ... Behalf of the CISA Study Group (2021). Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. *AIDS patient care and STDs*, 35(9), 342–353. <https://doi.org/10.1089/apc.2021.0089>
26. Fabbiani, M., Rossetti, B., Ciccullo, A., Oreni, L., Lagi, F., Celani, L., Colafigli, M., **De Vito, A.**, Mazzitelli, M., Dusina, A., Durante, M., Montagnani, F., Rusconi, S., Capetti, A., Sterrantino, G., D'Ettore, G., Di Giambenedetto, S., & ODOACRE Study Group (2021). Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. *HIV medicine*, 22(9), 843–853. <https://doi.org/10.1111/hiv.13146>
27. Fiore, V., **De Vito, A.**, Pontali, E., Lucania, L., Madeddu, G., & Babudieri, S. (2021). Chronic Viral Hepatitis in the Italian Prison Setting: Prevalence, Outcomes, Literature Needs and Perspectives. *Healthcare (Basel, Switzerland)*, 9(9), 1186. <https://doi.org/10.3390/healthcare9091186>
28. Mazzitelli M, Ciccullo A, Baldin G, Cauda R, Rusconi S, Giacomelli A, Oreni L, Borghi V, Mussini C, Guaraldi G, Sterrantino G, Lagi F, Candelaresi B, Cirioni O, **De Vito A**, Rossetti B, Torti C, Di Giambenedetto S. Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. *Medicine (Baltimore)*. 2021 Oct 15;100(41):e27418. <https://doi.org/10.1097/MD.00000000000027418>.
29. Fiore V, **De Vito A**, Fanelli C, Geremia N, Princic E, Nivoli A, Maida I, Loretto L, Madeddu G, Babudieri S: Mood Reactive Disorders among COVID-19 Inpatients: Experience from a Monocentric Cohort. *Med Princ Pract* 2021. doi: 10.1159/000518490
30. Ciccullo A, Borghi V, Giacomelli A, Cossu MV, Sterrantino G, Latini A, Giacometti A, **De Vito A**, Gennari W, Madeddu G, Capetti A, d'Ettore G, Mussini C, Rusconi S, Di Giambenedetto S, Baldin G. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. *J Acquir Immune Defic Syndr*. 2021 Nov 1;88(3):234-237. <https://doi.org/10.1097/QAI.0000000000002787>.
31. Vaira LA, **De Vito A**, Lechien JR, Chiesa-Estomba CM, Mayo-Yañez M, Calvo-Henríquez C, Saussez S, Madeddu G, Babudieri S, Boscolo-Rizzo P, Hopkins C, De Riu G. New Onset of Smell and Taste Loss Are Common Findings Also in Patients With Symptomatic COVID-19 After Complete Vaccination. *Laryngoscope*. 2022 Feb;132(2):419-421. doi: 10.1002/lary.29964. Epub 2021 Nov 26. PMID: 34812498; PMCID: PMC9011575.
32. Vaira LA, **De Vito A**, Deiana G, Pes C, Giovanditto F, Fiore V, Lechien JR, Le Bon SD, Saussez S, Madeddu G, Babudieri S, Pazzola A, Bandiera F, Fois AG, Piana AF, Hopkins C, De Riu G. Correlations between IL-6 serum level and olfactory dysfunction severity in COVID-19 patients: a preliminary study. *Eur Arch Otorhinolaryngol*. 2022 Feb; 279: 811-816. doi: 10.1007/s00405-021-06868-5.
33. Vaira, L.A., **De Vito, A.**, Lechien, J.R., Chiesa-Estomba, C.M., Mayo-Yañez, M., Calvo-Henríquez, C., Boscolo-Rizzo, P., Hopkins, C. and De Riu, G. (2021), In Response to Smell and Taste Loss in COVID-19 After Complete Vaccination: Correspondence. *The Laryngoscope*. <https://doi.org/10.1002/lary.29991>
34. **De Vito, A.**, Botta, A., Berruti, M., Castelli, V., Lai, V., Cassol, C., Lanari, A., Stella, G., Shallvari, A., Bezenchek, A., Di Biagio, A. Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance

Test from a Multicenter Italian Cohort. *J. Pers. Med.* 2022, 12, 188.

<https://doi.org/10.3390/jpm12020188>

35. Fiore V., Beretta R., **De Vito A.**, Barac A., Maida I., Joeseeph Kelvin DD., Piu C., Lai V., Madeddu G., Rubino S., Stevanovic G., Korica S., Babudieri S. Emerging Clinical Features of COVID-19 Related Pancreatitis: Case Reports and Review of the Literature. *Front Med (Lausanne)*. 2022 Jan 18;8:779118. <https://doi.org/10.3389/fmed.2021.779118>.
36. Bavaro DF, **De Vito A.**, Pasculli G, Bouba Y, Magnasco L, Pincino R, Saladini F, Lattanzio R, Corsini R, Arima S, Zazzi M, Incardona F, Rossetti B, Bezenchek A, Vanni B, Di Biagio A. Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study. *J Med Virol.* 2022 Mar 31. doi: 10.1002/jmv.27754
37. Boscolo-Rizzo P, Tirelli G, Meloni P, Hopkins C, Madeddu G, **De Vito A.**, Gardenal N, Valentinotti R, Tofanelli M, Borsetto D, Lechien JR, Polesel J, De Riu G, Vaira LA. Coronavirus disease 2019 (COVID-19)-related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Omicron variant. *Int Forum Allergy Rhinol.* 2022 Mar 14. doi: 10.1002/alr.22995.
38. Magnasco L, Pincino R, Pasculli G, Bouba Y, Saladini F, Bavaro DF, **De Vito A.**, Lattanzio R, Corsini R, Zazzi M, Incardona F, Rossetti B, Bezenchek A, Borghi V, Di Biagio A. Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen. *AIDS Res Hum Retroviruses.* 2022 Feb 10. doi: 10.1089/AID.2021.0016.
39. **De Vito A.**, Colpani A, Zauli B, Meloni MC, Fois M, Fiore V, Pintus GA, Nardi VG, Babudieri S, Madeddu G. How Little Do We Know about HIV and STIs Prevention? Results from a Web-Based Survey among the General Population. *Healthcare* 2022, 10, 1059. <https://doi.org/10.3390/healthcare10061059>
40. **De Vito A.**, Fiore V, Urru V, Bozzi E, Geremia N, Princic E, Canu D, Mollicotti P, Are R, Babudieri S, Madeddu G. Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report. *Braz J Infect Dis.* 2022 Sep-Oct;26(5):102701. doi: 10.1016/j.bjid.2022.102701. Epub 2022 Sep 10. PMID: 36096158; PMCID: PMC9520218.
41. Melis F, **De Vito A.**, Fiore V, et al. Is oral antibiotic therapy as effective as intravenous treatment in bacterial osteomyelitis? A real-life experience. *Eur Rev Med Pharmacol Sci.* 2022;26(11):4069-4073. doi:10.26355/eurrev_202206_28976
42. Marongiu A., Nuvoli S., **De Vito A.**, Rondini M., Spanu A., Madeddu G. (2022). A Comparative Follow-Up Study of Patients with Papillary Thyroid Carcinoma Associated or Not with Graves' Disease. *Diagnostics (Basel, Switzerland)*, 12(11), 2801. <https://doi.org/10.3390/diagnostics12112801>
43. Fiore V, **De Vito A.**, Bagella P, et al. Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study. *Healthcare (Basel)*. 2022;10(5):956. Published 2022 May 22. doi:10.3390/healthcare10050956
44. **De Vito A.**, Colpani A., Bitti A., Zauli B., Meloni M., C., Fois M., Denti L., Bacciu S., Marcia C., Maida I., Babudieri S., & Madeddu G. (2022). Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience. *Journal of medical virology*, 10.1002/jmv.28011. Advance online publication. <https://doi.org/10.1002/jmv.28011>
45. Fiore V., Rastrelli E., Madeddu G., Ranieri R., **De Vito A.**, Giuliani R., Di Mizio G., Bolcato M., De Matteis G., Ialungo A., M., Dell'Isola S., Starnini G., & Babudieri S. (2022). HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects. *BMC infectious diseases*, 22(1), 601. <https://doi.org/10.1186/s12879-022-07565-2>

46. **De Vito A.**, Polisenio M., Colpani A., Zauli B., Puci M., V., Santantonio T., Meloni M., C., Fois M., Fanelli C., Saderi L., Fois A., Fiore V., Sotgiu G., Babudieri S., Lo Caputo S., & Madeddu G. (2022). Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study. *Current medical research and opinion*, 1–15. Advance online publication. <https://doi.org/10.1080/03007995.2022.2129801>
47. Geremia N., **De Vito A.**, Lai V., Fiore V., Princic E., Rappelli P., Madeddu G., & Babudieri S. (2022). Human urogenital schistosomiasis in West and Sub-Saharan Africa migrants in Sardinia, Italy: A retrospective monocentric study. *Journal of infection in developing countries*, 16(8), 1359–1363. <https://doi.org/10.3855/jidc.15492>
48. Fiore V., **De Vito A.**, Colpani A., Manca V., Maida I., Madeddu G., Babudieri S. (2022). Viral Hepatitis C New Microelimination Pathways Objective: Psychiatric Communities HCV Free. *Life (Basel, Switzerland)*, 12(11), 1873. <https://doi.org/10.3390/life12111873>
49. Fiore V., De Matteis G., Pontali, E., **De Vito A.**, Panese S., Geremia N., Maida I., Artioli S., Starnini G., Madeddu G., Babudieri S. (2022). Quick diagnosis, staging, and treatment of HCV infection among people living in prison: Opinion expert panel. *Frontiers in public health*, 10, 926414. <https://doi.org/10.3389/fpubh.2022.926414>
50. **De Vito A.**, Saderi L, Fiore V, Geremia N, Princic E, Fanelli C, Muredda AA, Panu Napodano C, Moi G, Maida I, Fois AG, Sotgiu G, Madeddu G, Babudieri S. Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients. *Panminerva Med.* 2023 Sep;65(3):286-291. doi: 10.23736/S0031-0808.22.04572-4. Epub 2022 May 27. PMID: 35622392.
51. **De Vito A.**, Colpani A., Saderi L., Puci M., Zauli B., Fiore V., Fois M., Meloni M. C., Bitti A., Di Castri C., Maida I., Babudieri S., Sotgiu G., Madeddu G. (2023). Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression. *Viruses*, 15(1), 71. <https://doi.org/10.3390/v15010071>
52. **De Vito A.**, Colpani A., Saderi L., Puci M., Zauli B., Meloni M. C., Fois M., Bitti A., Di Castri C., Fiore V., Maida I., Babudieri S., Sotgiu G., Madeddu, G. (2023). Is the 4C Score Still a Valid Item to Predict In-Hospital Mortality in People with SARS-CoV-2 Infections in the Omicron Variant Era?. *Life (Basel, Switzerland)*, 13(1), 183. <https://doi.org/10.3390/life13010183>
53. Rastrelli E.; Fiore V.; Ranieri R.; Pontali E.; Prestileo T.; Barbarini G.; Ialungo A.M.; Dell’Isola S.; **De Vito A.**; Bolcato M.; Madeddu G.; Di Mizio G.; Starnini G.; Babudieri S., on behalf of ROSE Network. Women Living with HIV in Italian Prison Settings: Results from the Gender-Specific ROSE Network. *Viruses* 2023, 15, 497. <https://doi.org/10.3390/v15020497>
54. Fiore V, Manca V, Colpani A, **De Vito A**, Maida I, Madeddu G, Babudieri S. Facing HCV as a Major Public Healthcare Threat in Italy: Epidemiology and Micro-Elimination Pathways among Underserved Populations. *Healthcare (Basel)*. 2023 Jul 24;11(14):2109. doi: 10.3390/healthcare11142109.
55. **De Vito A.**; Colpani A.; Mameli M.S.; Bagella P.; Fiore V.; Fozza C.; Montesu M.A.; Fois A.G.; Filigheddu F.; Manzoni N.; Putzu C.; Babudieri S.; Madeddu, G. HIV Infection Indicator Disease-Based Active Case Finding in a University Hospital: Results from the SHOT Project. *Infect. Dis. Rep.* 2023, 15, 94-101. <https://doi.org/10.3390/idr15010010>
56. **De Vito A.**, Fiore, V., Colpani, A., Zauli, B., Fanelli, C., Tiseo, G., Occhineri, S., Babudieri, S., Falcone, M., & Madeddu, G. (2023). The current and future off-label uses of dalbavancin: a narrative review. *European review for medical and pharmacological sciences*, 27(3), 1222–1238. https://doi.org/10.26355/eurev_202302_31233
57. Colpani A, Donisi A, **De Vito A**, Zauli B, Fanelli C, Fiore V, Babudieri S, Madeddu G. Circulation of SARS-CoV-2 Among Asylum Seekers: A Real-Life Experience to Address Health Equity in Piacenza, Italy. *Infectious Diseases in Clinical Practice* 2023; 31 (1): e1173.

58. Donisi A, Colpani A, Zauli B, **De Vito A**, Fiore V, Babudieri S, Madeddu G. Sexually Transmitted Infections Prevalence and Cascade of Care among Undocumented Sex Workers: A Twenty-Year-Long Experience. *Life*. 2023; 13(3):606. <https://doi.org/10.3390/life13030606>
59. **De Vito A**, Ricci E, Menzaghi B, Orofino G, Martinelli CV, Squillace N, Taramasso L, De Socio GV, Molteni C, Valsecchi L, Costa C, Celesia BM, Parruti G, Pellicanò GF, Sarchi E, Cascio A, Cenderello G, Falasca K, Di Biagio A, Bonfanti P, Madeddu G. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study. *Viruses*. 2023; 15(3):720. <https://doi.org/10.3390/v15030720>
60. **De Vito A**, Colpani A, Trunfio M, Fiore V, Moi G, Fois M, Leoni N, Ruiiu S, Babudieri S, Calcagno A, Madeddu G. Living with HIV and Getting Vaccinated: A Narrative Review. *Vaccines*. 2023; 11(5):896. <https://doi.org/10.3390/vaccines11050896>
61. Berretta M, Facchini BA, Colpani A, Di Francia R, Montopoli M, Pellicanò G, Tirelli U, Fiorica F, Ottaiano A, Madeddu G, **De Vito A**. New treatment strategies for HIV-positive cancer patients undergoing anticancer medical treatment: update of the literature. *Eur Rev Med Pharmacol Sci*. 2023 May;27(9):4185-4201. https://doi.org/10.26355/eurrev_202305_32328
62. Boscolo-Rizzo P, Tirelli G, Meloni P, Hopkins C, Lechien JR, Madeddu G, Bonini P, Gardenal N, Cancellieri E, Lazzarin C, Borsetto D, **De Vito A**, De Riu G, Vaira LA. Recovery from olfactory and gustatory dysfunction following COVID-19 acquired during Omicron BA.1 wave in Italy. *Am J Otolaryngol*. 2023 Sep-Oct;44(5):103944. <https://doi.org/10.1016/j.amjoto.2023.103944>
63. **De Vito A**, Colpani A, Madeddu G. Shedding new light on COVID-19 therapeutics during the omicron era: a deeper dive into real-world data. *Lancet Reg Health Eur*. 2023 Jul 18;31:100694. <https://doi.org/10.1016/j.lanepe.2023.100694>
64. Colpani A, **De Vito A**, Madeddu G. Special Issue "Efficacy and Safety of Antiviral Therapy". *Viruses*. 2023 Jun 21;15(7):1411. <https://doi.org/10.3390/v15071411>
65. Cervo A, Russo A, Di Carlo D, **De Vito A**, Fabeni L, D'Anna S, Duca L, Colpani A, Fois M, Zauli B, Mancarella G, Carraro A, Bezenchek A, Cozzi-Lepri A, Santoro MM; ARCA Study Group. Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort. *J Glob Antimicrob Resist*. 2023 Jul 13;34:141-144. <https://doi.org/10.1016/j.jgar.2023.07.006>
66. **De Vito A**, Colpani A, Polisenio M, Diella L, Ieva FRP, Belati A, Papale R, Babudieri S, De Santis L, Saracino A, Lo Caputo S, Madeddu G. What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study. *Viruses*. 2023 Aug 17;15(8):1757. doi: 10.3390/v15081757.
67. Giacomelli A, Gagliardini R, Tavelli A, De Benedittis S, Mazzotta V, Rizzardini G, Mondì A, Augello M, Antinori S, Vergori A, Gori A, Menozzi M, Taramasso L, Fusco FM, **De Vito A**, Mancarella G, Marchetti G, Monforte AD, Antinori A, Cozzi-Lepri A; COVID-19 ICONA study group. Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the Icona network. *Int J Infect Dis*. 2023 Sep 21:S1201-9712(23)00728-2. doi: 10.1016/j.ijid.2023.09.015.
68. Marongiu A, Nuvoli S, **De Vito A**, Vargiu S, Spanu A, Madeddu G. Hashimoto's Thyroiditis and Papillary Thyroid Carcinoma: A Follow-Up Study in Patients with Absence of Aggressive Risk Factors at the Surgery of the Primary Tumor. *Diagnostics*. 2023; 13(19):3068. <https://doi.org/10.3390/diagnostics13193068>
69. Doszhanova G, Colpani A, Duisenova A, **De Vito A**, Zholdybay Z, Juszkievicz K, Brunetti E, Katarbayev A, Kaniyev S, Zhakenova Z, Manciuilli T, Mustapayeva A. The high burden of pediatric cystic echinococcosis in Kazakhstan: epidemiological and clinical consequences. *Trans R Soc Trop Med Hyg*. 2023 Sep 18:trad065. doi: 10.1093/trstmh/trad065.
70. Vergori A., Tavelli A., Matusali G., Azzini A. M., Augello M., Pellicanò G. F., Costantini A., Cascio A., **De Vito A**, Marconi L., Righi E., Sartor A., Pinnetti C., Maggi F., Bai F., Lanini S.,

Piconi S., Levy Hara G., Marchetti G., Giannella M., Tacconelli E., d'Arminio Monforte A., Antinori A., Cozzi-Lepri A. SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio. *Vaccines* 2023, *11*, 1664. <https://doi.org/10.3390/vaccines11111664>

71. Lagi F, Giacomelli A, Borghi V, Ciccullo A, Taramasso L, Madeddu G, D'Ettorre G, Giacometti A, Ducci F, **De Vito A**, Pincino R, Di Giambenedetto S, Mussini C, Antinori S, Sterrantino G. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study. *J Med Virol.* 2023 Oct;95(10):e29149. doi: 10.1002/jmv.29149. PMID: 37805832.
72. Giovagnorio, F.; **De Vito, A.**; Madeddu, G.; Parisi, S.G.; Geremia, N. Resistance in *Pseudomonas aeruginosa*: A Narrative Review of Antibigram Interpretation and Emerging Treatments. *Antibiotics* 2023, *12*, 1621. <https://doi.org/10.3390/antibiotics12111621>
73. **De Vito A**, Moi G, Saderi L, Puci MV, Colpani A, Firino L, Puggioni A, Uzzau S, Babudieri S, Sotgiu G, et al. Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study. *Viruses.* 2023; *15*(11):2180. <https://doi.org/10.3390/v15112180>
74. Frallonardo L., Segala F. V., Chhaganlal K. D., Yelshazly M., Novara R., Cotugno S., Guido G., Papagni R., Colpani A., **De Vito A.**, Barbagallo M., Madeddu G., Babudieri S., Lochoro P., Ichtho J., Putoto G., Veronese N., Saracino A., Di Gennaro F. Incidence and burden of long COVID in Africa: a systematic review and meta-analysis. *Sci Rep* 13, 21482 (2023). <https://doi.org/10.1038/s41598-023-48258-3>
75. Fiore V, **De Vito A**, Rastrelli E, Manca V, De Matteis G, Ranieri R, Pontali E, Geremia N, Panese S, Starnini G, Madeddu G, Babudieri S. Differences in HCV Seroprevalence, Clinical Features, and Treatment Outcomes between Female and Male Incarcerated Population: Results from a Matched Cohort Study. *Viruses.* 2023 Dec 12;15(12):2414. doi: 10.3390/v15122414.
76. Fiore V, Manca V, **De Vito A**, Colpani A, Maida I, Madeddu G, Babudieri S. Quick diagnostic approach for HIV/STDs among migrants: results from a monocentric Italian cohort. *J Infect Dev Ctries.* 2023 Nov 30;17(11):1621-1625. doi: 10.3855/jidc.18317.
77. Marongiu A, Nuvoli S, **De Vito A**, Vargiu S, Spanu A, Madeddu G. Minimal Extrathyroid Extension (mETE) as the Only Risk Factor in Patients with Papillary Thyroid Carcinoma (PC): Its Clinical Impact on Recurrence and Outcome during Long-Term Follow-Up. *Biomedicines.* 2024; *12*(2):350. <https://doi.org/10.3390/biomedicines12020350>
78. Colpani A, **De Vito A**, Zauli B, Menzaghi B, Calcagno A, Celesia BM, Ceccarelli M, Nunnari G, De Socio GV, Di Biagio A, et al. Knowledge of Sexually Transmitted Infections and HIV among People Living with HIV: Should We Be Concerned? *Healthcare.* 2024; *12*(4):417. <https://doi.org/10.3390/healthcare12040417>
79. **De Vito A**, Saderi L, Colpani A, Puci MV, Zauli B, Fiore V, Fois M, Meloni MC, Bitti A, Moi G, Maida I, Babudieri S, Sotgiu G, Madeddu G. New score to predict COVID-19 progression in vaccine and early treatment era: the COVID-19 Sardinian Progression Score (CSPS). *Eur J Med Res.* 2024 Feb 15;29(1):123. doi: 10.1186/s40001-024-01718-6. PMID: 38360688; PMCID: PMC10868088.
80. Geremia N, Giovagnorio F, **De Vito A**, Martignago L, Fiore V, Rastrelli E, Madeddu G, Parisi SG, Starnini G, Panese S, et al. HBV in Italian Women's Jail: An Underestimated Problem? *Journal of Clinical Medicine.* 2024; *13*(5):1398. <https://doi.org/10.3390/jcm13051398>
81. **De Vito A**, Colpani A, Moi G, Babudieri S, Calcagno A, Calvino V, Ceccarelli M, Colpani G, d'Ettorre G, Di Biagio A, Farinella M, Falaguasta M, Focà E, Giupponi G, Habed AJ, Isenia WJ, Lo Caputo S, Marchetti G, Modesti L, Mussini C, Nunnari G, Rusconi S, Russo D,

- Saracino A, Serra PA, Madeddu G. Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity. *AIDS Behav.* 2024 Jun 5. doi: 10.1007/s10461-024-04391-2. Epub ahead of print. PMID: 38836986.
82. Geremia N, Giovagnorio F, Colpani A, **De Vito A**, Caruana G, Meloni MC, Madeddu G, Panese S, Parisi SG. What do We Know about Cryptic Aspergillosis? *Microorganisms.* 2024 Apr 28;12(5):886. doi: 10.3390/microorganisms12050886. PMID: 38792716; PMCID: PMC11124275.
 83. Iannone V, Ciccullo A, Moschese D, Giacomelli A, Fabbiani M, Lagi F, Papalini C, **De Vito A**, Cossu MV, Di Giambenedetto S, Borghetti A. Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort. *J Acquir Immune Defic Syndr.* 2024 Jun 1;96(2):e10-e11. doi: 10.1097/QAI.0000000000003427. PMID: 38771757.
 84. Fois M, **De Vito A**, Cherchi F, Ricci E, Pontolillo M, Falasca K, Corti N, Comelli A, Bandera A, Molteni C, et al. Efficacy and Safety of Ceftazidime–Avibactam Alone versus Ceftazidime–Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort. *Antibiotics.* 2024; 13(7):616. <https://doi.org/10.3390/antibiotics13070616>
 85. **De Vito A**, Geremia N, Marino A, Bavaro DF, Caruana G, Meschiari M, Colpani A, Mazzitelli M, Scaglione V, Venanzi Rullo E, Fiore V, Fois M, Campanella E, Pistarà E, Faltoni M, Nunnari G, Cattelan A, Mussini C, Bartoletti M, Vaira LA, Madeddu G. Assessing ChatGPT's theoretical knowledge and prescriptive accuracy in bacterial infections: a comparative study with infectious diseases residents and specialists. *Infection.* 2024 Jul 12. doi: 10.1007/s15010-024-02350-6. Epub ahead of print. PMID: 38995551.
 86. Geremia N, Basso M, **De Vito A**, Scaggiante R, Giobbia M, Battagin G, Dal Bello F, Giordani MT, Nardi S, Malena M, et al. Patterns of Transmitted Drug Resistance Mutations and HIV-1 Subtype Dynamics in ART-Naïve Individuals in Veneto, Italy, from 2017 to 2024. *Viruses.* 2024; 16(9):1393. <https://doi.org/10.3390/v16091393>
 87. Segala, F. V., Di Gennaro, F., Giannini, L. A. A., Stroffolini, G., Colpani, A., **De Vito, A.**, Di Gregorio, S., Frallonardo, L., Guido, G., Novara, R., Amendolara, A., Ritacco, I. A., Ferrante, F., Masini, L., Iannetti, I., Mazzeo, S., Marelllo, S., Veronese, N., Gobbi, F., Iatta, R., ... Saracino, A. (2024). Perspectives on climate action and the changing burden of infectious diseases among young Italian doctors and students: a national survey. *Frontiers in public health*, 12, 1382505. <https://doi.org/10.3389/fpubh.2024.1382505>
 88. De Vita, E., Segala, F.V., Frallonardo, L., Civile, G., De Scisciolo, D., Novara, R., **De Vito, A.**, De Girolamo, M.G., Amendolara, A., Piccolomo, L., Madeddu, G., Terranova, A., Mariani, D., Altavilla, S., Veronese, N., Barbagallo, M., Cicolini, G., Di Gennaro, F. and Saracino, A. (2024). Knowledge, Attitudes, and Practices toward Antimicrobial Resistance among Young Italian Nurses and Students: A Multicenter, Cross-Sectional Study. *Annals of Global Health*, 90(1), 46. <https://doi.org/10.5334/aogh.4488>
 89. Geremia N, Basso M, **De Vito A**, Scaggiante R, Giobbia M, Battagin G, Dal Bello F, Giordani MT, Nardi S, Malena M, Cattelan A, Parisi SG. Patterns of Transmitted Drug Resistance Mutations and HIV-1 Subtype Dynamics in ART-Naïve Individuals in Veneto, Italy, from 2017 to 2024. *Viruses.* 2024 Aug 30;16(9):1393. <https://doi.org/10.3390/v16091393>
 90. Geremia N, Giovagnorio F, Colpani A, **De Vito A**, Botan A, Stroffolini G, Toc DA, Zerbato V, Principe L, Madeddu G, Luzzati R, Parisi SG, Di Bella S. Fluoroquinolones and Biofilm: A Narrative Review. *Pharmaceuticals (Basel).* 2024 Dec 11;17(12):1673. <https://doi.org/10.3390/ph17121673>.
 91. Colpani A, **De Vito A**, Marino A, Ceccarelli M, Celesia BM, Conti GN, Spampinato S, Moi G, Venanzi Rullo E, Pellicanò GF, Sofia SA, Pantò G, Iacobello C, Frasca CM, Montineri A, Albanese A, Angioni G, Cacopardo B, Madeddu G, Nunnari G, On Behalf Of Sardinian Hiv

- Network And Sicilian Hiv Cohort SHiNe-SHiC Research Group. Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort. *Biomedicines*. 2024 Oct 11;12(10):2311. <https://doi.org/10.3390/biomedicines12102311>
92. Colpani, A.; Astorri, D.; **De Vito, A.**; Madeddu, G.; Panese, S.; Geremia, N. Tuberculosis-Induced Immune-Mediated Necrotizing Myopathy: A Challenging Case Scenario in a Non-Endemic Country. *Reports* 2024, 7, 82. <https://doi.org/10.3390/reports7040082>
 93. Vaira LA, Lechien JR, Abbate V, Gabriele G, Frosolini A, **De Vito A**, Maniaci A, Mayo-Yáñez M, Boscolo-Rizzo P, Saibene AM, Maglitto F, Salzano G, Califano G, Troise S, Chiesa-Estomba CM, De Riu G. Enhancing AI Chatbot Responses in Health Care: The SMART Prompt Structure in Head and Neck Surgery. *OTO Open*. 2025 Jan 16;9(1):e70075. <https://doi.org/10.1002/oto2.70075>
 94. **De Vito A**, Bezenchek A, Scutari R, Colagrossi L, Valenti G, Bellocchi MC, Pipitò L, Ferrara S, Malandrini S, Tallarita M, Cozzi-Lepri A, Silberstein FC, Caputo SL, Rusconi S. Assessing the Utilization of HIV Genotype Resistance Testing: Insight from Italian Infectious Diseases Units. *J Glob Antimicrob Resist*. 2025 Jan 28:S2213-7165(25)00022-0. <https://doi.org/10.1016/j.jgar.2025.01.018>
 95. Alberto Rizzo, Andrea De Vito, Riccardo Lucis, Davide Mileto, Andrea Giacomelli. Chain of thought reasoning in enhancing infectious disease diagnosis and microbiological analysis. *American Journal of Infection Control*, Volume 53, Issue 3, 411 – 412. <https://doi.org/10.1016/j.ajic.2024.11.009>
 96. De Vito A, Tavelli A, Cozzi-Lepri A, Giacomelli A, Rossotti R, Ponta G, Bobbio N, Ianniello A, Cingolani A, Madeddu G, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group. Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort. *HIV Med*. 2025 Jun;26(6):970-977. <https://doi.org/10.1111/hiv.70037>
 97. De Vito A, Geremia N, Marino A, Bavaro DF, Caruana G, Meschiari M, Colpani A, Mazzitelli M, Scaglione V, Venanzi Rullo E, Fiore V, Fois M, Campanella E, Pistarà E, Faltoni M, Nunnari G, Cattelan A, Mussini C, Bartoletti M, Vaira LA, Madeddu G. Assessing ChatGPT's theoretical knowledge and prescriptive accuracy in bacterial infections: a comparative study with infectious diseases residents and specialists. *Infection*. 2025 Jun;53(3):873-881. <https://doi.org/10.1007/s15010-024-02350-6>
 98. Soddu M, De Vito A, Madeddu G, Nicolosi B, Provenzano M, Ivziku D, Curcio F. Assessing the Accuracy, Completeness and Safety of ChatGPT-4o Responses on Pressure Injuries in Infants: Clinical Applications and Future Implications. *Nurs Rep*. 2025 Apr 14;15(4):130. <https://doi.org/10.3390/nursrep15040130>
 99. Geremia N, Marino A, De Vito A, Giovagnorio F, Stracquadanio S, Colpani A, Di Bella S, Madeddu G, Parisi SG, Stefani S, Nunnari G. Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options. *Antibiotics (Basel)*. 2025 Mar 16;14(3):306. <https://doi.org/10.3390/antibiotics14030306>
 100. De Vito A, Geremia N, Bavaro DF, Seo SK, Laracy J, Mazzitelli M, Marino A, Maraolo AE, Russo A, Colpani A, Bartoletti M, Cattelan AM, Mussini C, Parisi SG, Vaira LA, Nunnari G, Madeddu G. Comparing large language models for antibiotic prescribing in different clinical scenarios: which performs better? *Clin Microbiol Infect*. 2025 Mar 19:S1198-743X(25)00120-X. <https://doi.org/10.1016/j.cmi.2025.03.002>

1. PLOS-ONE 42
2. Infectious Diseases & Tropical Medicine 150
3. European Journal of Medical Research 30
4. Current Medical Research and Opinion 37
5. Journal of Medical Virology 20
6. Journal of Infection in Developing Countries 10
7. International Journal of Dermatology 9
8. Viruses 10
9. International Journal of Antimicrobial Agents 8
10. BMC Infectious Diseases 5
11. Expert Review of Anti-infective Therapy 5
12. European Review for Medical and Pharmacological Sciences: 5
13. Vaccines 5
14. Infectious Diseases 2
15. Lancet HIV 2
16. PEC 2
17. eClinicalMedicine: 2
18. Journal of Public Health and Emergency 1
19. International Journal of Immunopathology and Pharmacology 1
20. Healthcare 1
21. Frontiers in Microbiology 1
22. Infectious Diseases in Clinical Practice 1
23. Frontiers in Pediatrics 1
24. Frontiers in Public Health 1
25. Frontiers in Medicine 1
26. Expert Review of Pharmacoeconomics & Outcomes Research 1
27. AIDS Research and Human Retroviruses 1
28. Patient Education and Counseling 1
29. Pathogens 1
30. Endocrine 1
31. Frontiers Cellular and Infection Microbiology 1
32. Life 1
33. Antibiotics 1
34. International Journal of Environmental Research and Public Health 1
35. Diagnostics 1
36. Applied microbiology 1
37. Acta Oto-Laryngologica 1
38. Journal of Personalized Medicine 1
39. The Lancet Regional Health – Europe 1
40. Expert Opinion On Drug Metabolism and Toxicology 1
41. Osong Public Health and Research Perspectives:1
42. AIDS and Behaviour: 3
43. JAIDS Journal of Acquired Immune Deficiency Syndromes: 1
44. International Journal of Environmental Research and Public Health:1
45. HIV Research & Clinical Practice: 1

Editor activity for indexed journals:

1. Section Editor for European Journal of Medical Research
(<https://eurjmedres.biomedcentral.com/about/editorial-board>)
2. Section Editor for Infectious Diseases and Tropical Medicine
(<https://www.infectiousjournal.com/editors-and-editorial-board>)
3. Special Editor for Viruses, special issue “Adverse Effects of Antiretroviral Therapy”
(https://www.mdpi.com/journal/viruses/special_issues/Adverse_Effects_Antiretroviral_Therapy)
4. Special Editor for Viruses, special issue “Efficacy and Safety of Antiviral Therapy”
(https://www.mdpi.com/journal/viruses/special_issues/227R0T5R5T)
5. Special Editor for Life, special issue “HIV and STIs Prevention”
(https://www.mdpi.com/journal/life/special_issues/9C62005I6F)
6. Special Editor for Viruses, special issue “Efficacy and Safety of Antiviral Therapy 2nd Edition” (https://www.mdpi.com/journal/viruses/special_issues/691A038TC0)
7. International Advisory Board for Current Medical Research and Opinion
(<https://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=icmo20>)
8. Collection Editor for Viruses, Collection “Efficacy and Safety of Antiviral Therapy”
(https://www.mdpi.com/journal/viruses/topical_collections/6CZI08528Y)

Metrix (from Scopus: last update 11/03/2025)

N° of documents: 101

Citations: 1728

H-index: 21

Data 25/06/2025

